Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 1/2018

01-03-2018

miR-155 in cancer drug resistance and as target for miRNA-based therapeutics

Authors: Recep Bayraktar, Katrien Van Roosbroeck

Published in: Cancer and Metastasis Reviews | Issue 1/2018

Login to get access

Abstract

Small non-coding microRNAs (miRNAs) are instrumental in physiological processes, such as proliferation, cell cycle, apoptosis, and differentiation, processes which are often disrupted in diseases like cancer. miR-155 is one of the best conserved and multifunctional miRNAs, which is mainly characterized by overexpression in multiple diseases including malignant tumors. Altered expression of miR-155 is found to be associated with various physiological and pathological processes, including hematopoietic lineage differentiation, immune response, inflammation, and tumorigenesis. Furthermore, miR-155 drives therapy resistance mechanisms in various tumor types. Therefore, miR-155-mediated signaling pathways became a potential target for the molecular treatment of cancer. In this review, we summarize the current findings of miR-155 in hematopoietic lineage differentiation, the immune response, inflammation, and cancer therapy resistance. Furthermore, we discuss the potential of miR-155-based therapeutic approaches for the treatment of cancer.
Literature
1.
2.
Ha, M., & Kim, V. N. (2014). Regulation of microRNA biogenesis. Nature Reviews. Molecular Cell Biology, 15(8), 509–524.PubMedCrossRef
3.
Bayraktar, R., et al. (2017). MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. Oncotarget, 8(7), 11641–11658.PubMedCrossRef
4.
Kanlikilicer, P., et al. (2016). Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells. Cancer Research, 76(24), 7194–7207.PubMedCrossRef
5.
Mangala, L. S., et al. (2016). Improving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapy. JCI Insight, 1(17), e87754.PubMedPubMedCentralCrossRef
6.
Rashed, M. H., et al. (2017). Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. Oncotarget, 8(12), 20145–20164.PubMedPubMedCentralCrossRef
7.
Bentwich, I., et al. (2005). Identification of hundreds of conserved and nonconserved human microRNAs. Nature Genetics, 37(7), 766–770.PubMedCrossRef
8.
Calin, G. A., & Croce, C. M. (2006). MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene, 25(46), 6202–6210.PubMedCrossRef
9.
Calin, G. A., et al. (2002). Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 99(24), 15524–15529.PubMedPubMedCentralCrossRef
10.
Van Roosbroeck, K., & Calin, G. A. (2016). MicroRNAs in chronic lymphocytic leukemia: miRacle or miRage for prognosis and targeted therapies? Seminars in Oncology, 43(2), 209–214.PubMedPubMedCentralCrossRef
11.
Van Roosbroeck, K., Pollet, J., & Calin, G. A. (2013). miRNAs and long noncoding RNAs as biomarkers in human diseases. Expert Review of Molecular Diagnostics, 13(2), 183–204.PubMedCrossRef
12.
Chen, S., et al. (2015). Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism. Cancer Research, 75(3), 519–531.PubMedCrossRef
13.
Haasch, D., et al. (2002). T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC. Cell Immunol, 217(1–2), 78–86.PubMedCrossRef
14.
Babar, I. A., et al. (2012). Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 109(26), E1695–E1704.PubMedPubMedCentralCrossRef
15.
Faraoni, I., et al. (2009). miR-155 gene: a typical multifunctional microRNA. Biochimica et Biophysica Acta, 1792(6), 497–505.PubMedCrossRef
16.
Gironella, M., et al. (2007). Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proceedings of the National Academy of Sciences of the United States of America, 104(41), 16170–16175.PubMedPubMedCentralCrossRef
17.
Kong, W., et al. (2014). Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene, 33(6), 679–689.PubMedCrossRef
18.
O’Connell, R. M., et al. (2009). Inositol phosphatase SHIP1 is a primary target of miR-155. Proceedings of the National Academy of Sciences of the United States of America, 106(17), 7113–7118.PubMedPubMedCentralCrossRef
19.
Tili, E., Croce, C. M., & Michaille, J. J. (2009). miR-155: on the crosstalk between inflammation and cancer. International Reviews of Immunology, 28(5), 264–284.PubMedCrossRef
20.
Tili, E., et al. (2011). Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proceedings of the National Academy of Sciences of the United States of America, 108(12), 4908–4913.PubMedPubMedCentralCrossRef
21.
Van Roosbroeck, K., et al. (2017). Combining anti-Mir-155 with chemotherapy for the treatment of lung cancers. Clinical Cancer Research, 23(11), 2891–2904.PubMedCrossRef
22.
Eis, P. S., et al. (2005). Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 102(10), 3627–3632.PubMedPubMedCentralCrossRef
23.
Lagos-Quintana, M., et al. (2002). Identification of tissue-specific microRNAs from mouse. Current Biology, 12(9), 735–739.PubMedCrossRef
24.
Tam, W. (2001). Identification and characterization of human BIC, a gene on chromosome 21 that encodes a noncoding RNA. Gene, 274(1–2), 157–167.PubMedCrossRef
25.
26.
Vargova, K., et al. (2011). MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. Blood, 117(14), 3816–3825.PubMedCrossRef
27.
Zhao, H., et al. (2017). Transforming growth factor beta1/Smad4 signaling affects osteoclast differentiation via regulation of miR-155 expression. Molecules and Cells, 40(3), 211–221.PubMedPubMedCentral
28.
Gerloff, D., et al. (2015). NF-kappaB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. Leukemia, 29(3), 535–547.PubMedCrossRef
29.
Georgantas III, R. W., et al. (2007). CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proceedings of the National Academy of Sciences of the United States of America, 104(8), 2750–2755.PubMedPubMedCentralCrossRef
30.
Masaki, S., et al. (2007). Expression patterns of microRNAs 155 and 451 during normal human erythropoiesis. Biochemical and Biophysical Research Communications, 364(3), 509–514.PubMedCrossRef
31.
32.
Taganov, K. D., et al. (2006). NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proceedings of the National Academy of Sciences of the United States of America, 103(33), 12481–12486.PubMedPubMedCentralCrossRef
33.
O'Connell, R. M., et al. (2007). MicroRNA-155 is induced during the macrophage inflammatory response. Proceedings of the National Academy of Sciences of the United States of America, 104(5), 1604–1609.PubMedPubMedCentralCrossRef
34.
Kurowska-Stolarska, M., et al. (2011). MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proceedings of the National Academy of Sciences of the United States of America, 108(27), 11193–11198.PubMedPubMedCentralCrossRef
35.
Jin, H. M., et al. (2014). MicroRNA-155 as a proinflammatory regulator via SHIP-1 down-regulation in acute gouty arthritis. Arthritis Research & Therapy, 16(2), R88.CrossRef
36.
Keir, M. E., et al. (2008). PD-1 and its ligands in tolerance and immunity. Annual Review of Immunology, 26, 677–704.PubMedCrossRef
37.
38.
Powles, T., et al. (2014). MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature, 515(7528), 558–562.PubMedCrossRef
39.
Yee, D., et al. (2017). MicroRNA-155 induction via TNF-alpha and IFN-gamma suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells. The Journal of Biological Chemistry, 292(50), 20683–20693.
40.
41.
42.
Lu, L. F., et al. (2009). Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity, 30(1), 80–91.PubMedPubMedCentralCrossRef
43.
Yang, L., et al. (2017). MiRNA-155 promotes proliferation by targeting caudal-type homeobox 1 (CDX1) in glioma cells. Biomedicine & Pharmacotherapy, 95, 1759–1764.CrossRef
44.
Liu, Q., et al. (2015). miR-155 regulates glioma cells invasion and chemosensitivity by p38 Isforms in vitro. Journal of Cellular Biochemistry, 116(7), 1213–1221.PubMedCrossRef
45.
D'Urso, P. I., et al. (2012). miR-155 is up-regulated in primary and secondary glioblastoma and promotes tumour growth by inhibiting GABA receptors. International Journal of Oncology, 41(1), 228–234.PubMed
46.
Xue, X., et al. (2016). MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN. Oncotarget, 7(51), 84508–84519.PubMedPubMedCentralCrossRef
47.
Liu, F., et al. (2017). MiR-155 inhibits proliferation and invasion by directly targeting PDCD4 in non-small cell lung cancer. Thorac Cancer, 8(6), 613–619.PubMedPubMedCentralCrossRef
48.
Al-Haidari, A. A., Syk, I., & Thorlacius, H. (2017). MiR-155-5p positively regulates CCL17-induced colon cancer cell migration by targeting RhoA. Oncotarget, 8(9), 14887–14896.PubMedPubMedCentralCrossRef
49.
Li, T., et al. (2014). miR-155 regulates the proliferation and cell cycle of colorectal carcinoma cells by targeting E2F2. Biotechnology Letters, 36(9), 1743–1752.PubMedCrossRef
50.
Fu, X., et al. (2017). MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway. Cancer Science, 108(4), 620–631.PubMedPubMedCentralCrossRef
51.
Xie, Q., et al. (2012). Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma. Cancer, 118(9), 2431–2442.PubMedCrossRef
52.
Liu, F., et al. (2015). MiR-155 targets TP53INP1 to regulate liver cancer stem cell acquisition and self-renewal. FEBS Letters, 589(4), 500–506.PubMedCrossRef
53.
Xiang, X., et al. (2011). miR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMT. Oncogene, 30(31), 3440–3453.PubMedPubMedCentralCrossRef
54.
Jiang, S., et al. (2010). MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Research, 70(8), 3119–3127.PubMedCrossRef
55.
Shen, R., et al. (2015). MiRNA-155 mediates TAM resistance by modulating SOCS6-STAT3 signalling pathway in breast cancer. American Journal of Translational Research, 7(10), 2115–2126.PubMedPubMedCentral
56.
Dinami, R., et al. (2014). miR-155 drives telomere fragility in human breast cancer by targeting TRF1. Cancer Research, 74(15), 4145–4156.PubMedCrossRef
57.
Tiago, D. M., et al. (2016). Matrix Gla protein repression by miR-155 promotes oncogenic signals in breast cancer MCF-7 cells. FEBS Letters, 590(8), 1234–1241.PubMedCrossRef
58.
Bhattacharya, S., et al. (2016). Increased miR-155-5p and reduced miR-148a-3p contribute to the suppression of osteosarcoma cell death. Oncogene, 35(40), 5282–5294.PubMedCrossRef
59.
Rather, M. I., et al. (2013). Oncogenic microRNA-155 down-regulates tumor suppressor CDC73 and promotes oral squamous cell carcinoma cell proliferation: implications for cancer therapeutics. The Journal of Biological Chemistry, 288(1), 608–618.PubMedCrossRef
60.
61.
Sandhu, S. K., et al. (2012). miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Emu-miR-155 transgenic mouse model. Proceedings of the National Academy of Sciences of the United States of America, 109(49), 20047–20052.PubMedPubMedCentralCrossRef
62.
Huang, X., et al. (2012). Quantitative proteomics reveals that miR-155 regulates the PI3K-AKT pathway in diffuse large B-cell lymphoma. The American Journal of Pathology, 181(1), 26–33.PubMedPubMedCentralCrossRef
63.
Pedersen, I. M., et al. (2009). Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas. EMBO Molecular Medicine, 1(5), 288–295.PubMedPubMedCentralCrossRef
64.
Willimott, S., & Wagner, S. D. (2012). miR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells. The Journal of Biological Chemistry, 287(4), 2608–2617.PubMedCrossRef
65.
Costinean, S., et al. (2009). Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood, 114(7), 1374–1382.PubMedPubMedCentralCrossRef
66.
67.
Merkel, O., et al. (2015). Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. The Journal of Pathology, 236(4), 445–456.PubMedPubMedCentralCrossRef
68.
Lawrie, C. H., et al. (2007). MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. International Journal of Cancer, 121(5), 1156–1161.PubMedCrossRef
69.
Fulci, V., et al. (2007). Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood, 109(11), 4944–4951.PubMedCrossRef
70.
Kluiver, J., et al. (2005). BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. The Journal of Pathology, 207(2), 243–249.PubMedCrossRef
71.
Faraoni, I., et al. (2012). MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status. Journal of Hematology & Oncology, 5, 26.CrossRef
72.
Costinean, S., et al. (2006). Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 103(18), 7024–7029.PubMedPubMedCentralCrossRef
73.
Rosenbauer, F., & Tenen, D. G. (2007). Transcription factors in myeloid development: balancing differentiation with transformation. Nature Reviews. Immunology, 7(2), 105–117.PubMedCrossRef
74.
Cui, B., et al. (2014). MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood, 124(4), 546–554.PubMedPubMedCentralCrossRef
75.
Ferrajoli, A., et al. (2013). Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood, 122(11), 1891–1899.PubMedPubMedCentralCrossRef
76.
Gatto, G., et al. (2008). Epstein-Barr virus latent membrane protein 1 trans-activates miR-155 transcription through the NF-kappaB pathway. Nucleic Acids Research, 36(20), 6608–6619.PubMedPubMedCentralCrossRef
77.
Lu, F., et al. (2008). Epstein-Barr virus-induced miR-155 attenuates NF-kappaB signaling and stabilizes latent virus persistence. Journal of Virology, 82(21), 10436–10443.PubMedPubMedCentralCrossRef
78.
Kluiver, J., et al. (2007). Regulation of pri-microRNA BIC transcription and processing in Burkitt lymphoma. Oncogene, 26(26), 3769–3776.PubMedCrossRef
79.
Garzon, R., et al. (2008). Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proceedings of the National Academy of Sciences of the United States of America, 105(10), 3945–3950.PubMedPubMedCentralCrossRef
80.
Salemi, D., et al. (2015). miR-155 regulative network in FLT3 mutated acute myeloid leukemia. Leukemia Research, 39(8), 883–896.PubMedCrossRef
81.
Wallace, J. A., et al. (2017). miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response. Blood, 129(23), 3074–3086.PubMedPubMedCentralCrossRef
82.
83.
Narayan, N., et al. (2017). Functionally distinct roles for different miR-155 expression levels through contrasting effects on gene expression, in acute myeloid leukaemia. Leukemia, 31(4), 808–820.PubMedCrossRef
84.
Volinia, S., et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America, 103(7), 2257–2261.PubMedPubMedCentralCrossRef
85.
Zhu, M., et al. (2011). Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage. Genome Biology, 12(8), R77.PubMedPubMedCentralCrossRef
86.
Neilsen, P. M., et al. (2013). Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. Oncogene, 32(24), 2992–3000.PubMedCrossRef
87.
Johansson, J., et al. (2013). MiR-155-mediated loss of C/EBPbeta shifts the TGF-beta response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer. Oncogene, 32(50), 5614–5624.PubMedPubMedCentralCrossRef
88.
Yanaihara, N., et al. (2006). Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell, 9(3), 189–198.PubMedCrossRef
89.
Zang, Y. S., et al. (2012). MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression. Cancer Gene Therapy, 19(11), 773–778.PubMedCrossRef
90.
Pouliot, L. M., et al. (2012). Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Research, 72(22), 5945–5955.PubMedPubMedCentralCrossRef
91.
Kong, W., et al. (2010). MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. The Journal of Biological Chemistry, 285(23), 17869–17879.PubMedPubMedCentralCrossRef
92.
Lei, C., et al. (2012). Up-regulated miR155 reverses the epithelial-mesenchymal transition induced by EGF and increases chemo-sensitivity to cisplatin in human Caski cervical cancer cells. PLoS One, 7(12), e52310.PubMedPubMedCentralCrossRef
93.
Lv, L., et al. (2016). Effect of miR-155 knockdown on the reversal of doxorubicin resistance in human lung cancer A549/dox cells. Oncology Letters, 11(2), 1161–1166.PubMedCrossRef
94.
Li, B., et al. (2017). Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis. Oncotarget, 8(29), 47849–47860.PubMedPubMedCentral
95.
Gu, S., et al. (2017). miR-155 mediates arsenic trioxide resistance by activating Nrf2 and suppressing apoptosis in lung cancer cells. Sci Rep, 7(1), 12155.PubMedPubMedCentralCrossRef
96.
Babar, I. A., et al. (2011). Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells. Cancer Biology & Therapy, 12(10), 908–914.CrossRef
97.
Khoshinani, H. M., et al. (2017). Involvement of miR-155/FOXO3a and miR-222/PTEN in acquired radioresistance of colorectal cancer cell line. Japanese Journal of Radiology, 35(11), 664–672.PubMedCrossRef
98.
Lv, X., et al. (2016). Inhibition of microRNA-155 sensitizes lung cancer cells to irradiation via suppression of HK2-modulated glucose metabolism. Molecular Medicine Reports, 14(2), 1332–1338.PubMedCrossRef
99.
Yang, F., Liu, Q., & Hu, C. M. (2015). Epstein-Barr virus-encoded LMP1 increases miR-155 expression, which promotes radioresistance of nasopharyngeal carcinoma via suppressing UBQLN1. European Review for Medical and Pharmacological Sciences, 19(23), 4507–4515.PubMed
100.
Gasparini, P., et al. (2014). Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. Proceedings of the National Academy of Sciences of the United States of America, 111(12), 4536–4541.PubMedPubMedCentralCrossRef
101.
Narita, M., et al. (2017). Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c. PLoS One, 12(2), e0172115.PubMedPubMedCentralCrossRef
102.
Chiu, C. F., et al. (2016). NF-kappaB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance. Proceedings of the National Academy of Sciences of the United States of America, 113(18), E2526–E2535.PubMedPubMedCentralCrossRef
103.
Kim, J. H., Kim, W. S., & Park, C. (2012). Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1. Leukemia & Lymphoma, 53(8), 1586–1591.CrossRef
104.
Pu, J., et al. (2012). Adrenaline promotes cell proliferation and increases chemoresistance in colon cancer HT29 cells through induction of miR-155. Biochemical and Biophysical Research Communications, 428(2), 210–215.PubMedCrossRef
105.
106.
Chen, L., et al. (2014). miR-155 mediates drug resistance in osteosarcoma cells via inducing autophagy. Experimental and Therapeutic Medicine, 8(2), 527–532.PubMedPubMedCentralCrossRef
107.
Patel, G. K., et al. (2017). Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK. Br J Cancer, 116(5), 609–619.PubMedCrossRef
108.
Mikamori, M., et al. (2017). MicroRNA-155 controls exosome synthesis and promotes gemcitabine resistance in pancreatic ductal adenocarcinoma. Scientific Reports, 7, 42339.PubMedPubMedCentralCrossRef
109.
Lei, H., & Quelle, F. W. (2009). FOXO transcription factors enforce cell cycle checkpoints and promote survival of hematopoietic cells after DNA damage. Molecular Cancer Research, 7(8), 1294–1303.PubMedCrossRef
110.
Lv, H., et al. (2014). miR-155 inhibitor reduces the proliferation and migration in osteosarcoma MG-63 cells. Experimental and Therapeutic Medicine, 8(5), 1575–1580.PubMedPubMedCentralCrossRef
111.
Feng, M., et al. (2015). Seed targeting with tiny anti-miR-155 inhibits malignant progression of multiple myeloma cells. Journal of Drug Targeting, 23(1), 59–66.PubMedCrossRef
112.
Meng, W., et al. (2012). Anti-miR-155 oligonucleotide enhances chemosensitivity of U251 cell to taxol by inducing apoptosis. Cell Biology International, 36(7), 653–659.PubMedCrossRef
113.
Choi, C. H., et al. (2012). Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells. Gynecologic Oncology, 126(1), 124–131.PubMedCrossRef
114.
Zhang, M., et al. (2013). Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma. Journal of Controlled Release, 168(3), 251–261.PubMedPubMedCentralCrossRef
115.
Mignacca, L., et al. (2016). Sponges against miR-19 and miR-155 reactivate the p53-Socs1 axis in hematopoietic cancers. Cytokine, 82, 80–86.PubMedCrossRef
116.
Khalife, J., et al. (2015). Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia. Leukemia, 29(10), 1981–1992.PubMedPubMedCentralCrossRef
117.
Querfeld, C., et al. (2016). Preliminary results of a phase II trial evaluating MRG-106, a synthetic microRNA antagonist (LNA antimiR) of microRNA-155, in patients with CTCL. Blood, 128(22), 1229.
118.
Catela Ivkovic, T., et al. (2017). microRNAs as cancer therapeutics: a step closer to clinical application. Cancer Letters, 407, 113–122.PubMedCrossRef
119.
Metadata
Title
miR-155 in cancer drug resistance and as target for miRNA-based therapeutics
Authors
Recep Bayraktar
Katrien Van Roosbroeck
Publication date
01-03-2018
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1/2018
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-017-9724-7

Other articles of this Issue 1/2018

Cancer and Metastasis Reviews 1/2018 Go to the issue

EditorialNotes

Preface

Correction

Correction to: Cancer driver G-protein coupled receptor (GPCR) induced β-catenin nuclear localization: the transcriptional junction

OriginalPaper

From biomarkers to therapeutic targets—the promises and perils of long non-coding RNAs in cancer

OriginalPaper

Long non-coding RNAs in metastasis

OriginalPaper

Non-coding RNAs, epigenetics, and cancer: tying it all together

OriginalPaper

Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits